Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 18/20 | 0.62 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.50 |
| ▸ | ABL1 | P00519 | 1/20 | 0.49 |
| ▸ | LCK | P06239 | 1/20 | 0.49 |
| ▸ | CSF1R | P07333 | 1/20 | 0.49 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.49 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.49 |
| ▸ | CDK7 | P50613 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7227876 | 0.91 | KDR (0.56) | KDRCHEK1ABL1LCKCSF1R | |
| SCHEMBL7234816 | 0.90 | KDR (0.66) | KDRCHEK1ABL1LCKCSF1R | |
| SCHEMBL7227731 | 0.89 | KDR (0.60) | KDRCHEK1ABL1LCKCSF1R | |
| SCHEMBL7236876 | 0.88 | KDR (0.58) | KDRCHEK1ABL1LCKCSF1R | |
| SCHEMBL7245889 | 0.87 | KDR (0.57) | KDRCHEK1ABL1LCKCSF1R | |
| SCHEMBL7228365 | 0.87 | KDR (0.60) | KDRCHEK1ABL1LCKCSF1R | |
| SCHEMBL7237730 | 0.86 | KDR (0.56) | KDRCHEK1ABL1LCKCSF1R | |
| SCHEMBL7235020 | 0.85 | KDR (0.54) | KDRCHEK1ABL1LCKCSF1R | |
| SCHEMBL7228482 | 0.84 | KDR (0.58) | KDRCHEK1ABL1LCKCSF1R | |
| SCHEMBL7237453 | 0.83 | KDR (0.61) | KDRCHEK1ABL1LCKCSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6586424-B2 | Anticancer agents; anticholesterol agents | MERCK & CO., INC. | 2003-07-01 | — | — | US | disclosed |
| US-6586423-B2 | 2-(Pyridin-2-ylamino)-thiazole-5-carbonitrile derivatives; angiogenesis inhibitors; antitumor and anticarcinogenic agents; atherosclerosis, macular degeneration, diabetic retinopathy | MERCK & CO., INC. | 2003-07-01 | — | — | US | disclosed |